reported that six months of SGLT2i therapy significantly reduced non-invasive liver fibrosis indices, circulating oxidative stress, and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), with no such effects observed in patients receiving other hypoglycemic therapies (38). The gene discussed is IL6; the disease is Hepatic fibrosis.